Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00408304|
Recruitment Status : Unknown
Verified December 2006 by Bnai Zion Medical Center.
Recruitment status was: Recruiting
First Posted : December 6, 2006
Last Update Posted : December 6, 2006
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hepatitis C||Drug: omega-3 fatty acid||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.|
|Study Start Date :||December 2006|
|Study Completion Date :||December 2007|
- The effect of omega three fatty acids would be estimated through two questionnaires which filled by the patients monthly
- with the BDI questionnaire which estimates the level of depression of the patient and
- the SF36 questionnaire which provides information about the overall influence of a disease upon a patient's daily life and mental status.
- Secondary outcome measures include monthly results of biochemical and hematologic blood tests, including levels of:
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00408304
|Bnai Zion Medical Center||Recruiting|
|Contact: Elad Schiff 97248359281 email@example.com|
|Principal Investigator: Elad Schiff|
|Principal Investigator:||Elad Schiff, MD||affiliated with Bnai Zion MC|